Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 1122 in its research report dated July 22, 2020.
Motilal Oswal 's research report on Alembic Pharma
Alembic Pharma (ALPM) delivered record revenue/EBITDA/PAT for 1QFY21 on the back of strong performance in Export Formulations/API and partly due to lower R&D spend for the quarter. ALPM remains on track in terms of completing capex, with ~INR15b spent over FY16–20 and a similar amount expensed for R&D. We expect the meaningful benefit to be reflected from 2HFY22.
We raise our EPS estimate by 20%/19.4% for FY21/FY22 to factor new launches in US Generics and a favorable outlook for Non-US Formulations/API sales. Accordingly, we revise our price target to INR1,100 (from INR975 earlier), valuing the stock on a 20x 12M forward earnings basis. Maintain Neutral stance on limited upside from current levels.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.